Objective-To assess the efficacy of a regional autologous blood donation programme.
Introduction
Autologous blood provides an alternative to blood from volunteer donors for patients undergoing elective surgical procedures. Although autologous transfusion has been practised intermittently for 100 years, there has recently been increased interest in the procedure. This has arisen partly from a heightened public awareness of the infective risk of blood transfusion and partly from the increasing demand for blood from volunteer donors. Potential advantages of autologous transfusion include the avoidance of blood transmitted infection, alloimmunisation, and transfusion related lung injury.
There is a small but definite risk of acquiring infection from transfused allogeneic blood. Dodd suggested that about three in 10 000 blood recipients in the United States contract serious or fatal transfusion transmitted infection.' Estimates of the risk of HIV transmission by transfusion in the United States range from one in 225 000 per unit transfused2 to one in 60000. 34 We have estimated the risk of HIV-1 transmission by allogeneic blood in the United Kingdom using Hickman's modification of a formula proposed by Ward et al.56 Using known incidences of HIV-1 antibody positivity between 1985 and 1991 of 0-004%/o in first time donors and 0-001% in repeat donors,7 we estimate the risk of HIV-1 transmission in the United Kingdom as one in 300 000 per unit transfused.
Hepatitis B remains a transfusion risk despite donor screening, but the annual number of acute cases in England and Wales is fairly small. On average 10 cases of acute hepatitis B in which patients had a recorded history of transfusion ( We report the first two years' experience of a preoperative autologous blood donation programme in a regional transfusion centre in the United Kindgom. We examine factors which prevented or limited provision of autologous blood and assess the incidence of subsequent autologous and allogeneic transfusions in autologous donors.
Patients and methods
The autologous blood donation programme was open to patients in the Northem Regional Health Authority who were waiting for a surgical procedure for which blood would usually be cross matched. Programme documentation was distributed to hospitals within the region. Hospitals within 40 miles (65 km) of the regional transfusion centre were particularly targeted. Patients were referred by surgeons using programme request forms. General practitioner requests were made in collaboration with the referring surgeon.
Patients were eligible for the study if they were considered sufficiently fit to donate blood on more than one occasion. There was no upper age limit. We excluded patients taking angiotensin converting enzyme inhibitors or with any of the following conditions: bacterial infection; unstable angina; angina at rest; severe hypertension; cardiac failure; myocardial infarction within the previous six months; anaemia (haemoglobin concentration < 110 g/l at the first visit or < 100 g/l at subsequent visits); aortic stenosis; symptomatic cardiac arrhythmia; severe left main stem coronary artery disease; transient ischaemic attacks; cerebrovascular accident; and severe chronic obstructive airways disease. All exclusions were listed on request forms. Entry of children aged less than 10 years was discouraged.
Assessment at the first visit included a medical history and measurements of blood pressure, pulse rate, and haemoglobin concentration. Fully informed, written consent was obtained for venesection and HIV testing. Patients A total of 151 referred patients did not donate (table  I) . In 73 cases the patient, general practitioner, or referring consultant decided against autologous donation before the patient attended the autologous clinic. Seventy eight patients were excluded by the transfusion centre medical officer, most commonly because of anaemia or ischaemic heart disease.
Of the 363 autologous procedures, 116 (32%) were performed in male patients and 247 (68%) in females. The median age was 59 years 1 month (range 10 years 10 months to 84 years 3 months). Table II shows the age distribution. The indications for entry into the programme are detailed in table III. In 245 (67%) of 363 procedures patients were taking medication which would have precluded voluntary allogeneic donation.
Collection of autologous blood-A total of 928 units of blood were collected (mean 2-6 units per procedure); 1135 autologous units had been requested (mean 3-1 units per procedure). Sixteen units were unsuitable for use (volume less than 405 ml (six cases), volume greater than 495 ml (one); time expired (six), processing error (three)). Thus 912 units (mean 2-5 units per procedure) were provided. The regional transfusion centre supplied 224 876 units of allogeneic blood during the study, so that the autologous programme 
Discussion
This programme allowed many patients having elective surgery to avoid transfusion with allogeneic blood. Most participating patients completely avoided allogeneic blood transfusion, and others received less allogeneic blood because autologous blood met part of their transfusion requirement. For these patients the small risk of infection or immunisation associated with allogeneic blood transfusion was reduced. The main objective of the programme was therefore achieved.
Eligibility criteria for autologous blood donation have been extensively debated, and several guidelines have been published."'-Our criteria may seem stringent when it is considered that all the patients were awaiting general anaesthesia and surgery. However, the avoidance of risk of allogeneic transfusion must be balanced against the risk of donation. In a patient with severe cardiovascular disease the risk of a hypotensive episode during donation may be judged to outweigh any benefit. The low incidence of adverse events in this and other series'4 's suggests that the risk of autologous donation is small. The slight excess of side effects from donation seen in older patients was not statistically significant and not associated with serious consequences. Other reports suggest that elderly people may be bled safely.' 6-' Although elderly patients seem well able to tolerate autologous donation, younger patients have more to gain as they have longer to reap the consequences of transfusion transmitted infection. Referral for autologous donation is dependent on hospital clinicians rather than transfusion centre staff, but we think that including a greater proportion of younger adults is logical. Children require special consideration as venesection may be difficult and increase apprehension associated with subsequent surgery.
Patients who donated the full requested quantity of blood subsequently received less allogeneic blood. Main causes of incomplete donation were late referral and anaemia. Late referral may be reduced by more effective communication between the programme organisers and referring clinicians. Anaemia is a more refractory problem. Erythropoietin has been used to enhance haemoglobin recovery during autologous procedures but experience is currently limited to small studies.'9-' Reducing the number of referred ineligible patients would benefit both the patients concemed and the service. The significant rate of non-attendance by patients suggests the need for improved patient counselling before entry into the programme.
An advantage of autologous transfusion is reduced demand for limited supplies of allogeneic blood. The impact of the autologous programme on the regional blood supply during the study was modest; it provided 0.4% of the blood issued by the Northem Region Blood Transfusion Service. It has been estimated that autologous blood could provide up to 10% of all blood requirements.22 BMJ VOLUME 305
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Autologous transfusion does not provide a cheaper alternative to transfusion of allogeneic blood. The cost of producing a unit of autologous blood in our centre is currently about twice the cost of an equivalent allogeneic unit. This difference is due to the staffing and transport costs of the autologous clinics, which are located at several hospitals within the region to allow easy access for patients. If the programme were to expand, allowing venesection of more donors at each clinic, the collection cost per unit would fall.
Unused autologous units were not made available for any other recipient. Most of our autologous donors were taking drugs which would make their blood donation unacceptable for allogeneic use. Also, most autologous units were transfused, those not transfused being held for potential autologous use until expiry or patient discharge. Thus very few units would ultimately be suitable for crossover and procedures for their retrieval are not justified.
We have shown the feasibility of a regional autologous donation programme coordinated by a blood transfusion centre. Main factors which prevented autologous donation were failure to attend the clinic, anaemia, and cardiovascular disease. The main factors which restricted the provision of blood by those who donated were late referral and post-donation anaemia. The aim of avoiding allogeneic blood transfusion was achieved by most patients who donated blood. Many of these studies were carried out on heterogeneous groups (homosexuals, drug misusers, haemophilic patients, family groups, etc), so that we still lack conclusive results. We report the role of heterosexual activity and of household contacts in the spread of hepatitis C virus as determined by studying viral markers in partners and other family members of anti-HCV positive blood donors without known risk factors.
Subjects, methods, and results
Eighty six blood donors (49 men) were evaluated based on the following criteria: presence of anti-HCV; absence of hepatitis B surface antigen and anti-HIV; no history of drug abuse; in a stable heterosexual relationship (range eight months to 40 years). The subjects were studied in two groups, group 1 being separated into subgroups la and lb. Subgroup la comprised 29 cases (16 men) ofhepatitis C virus related chronic hepatitis confirmed histologically or from a history of increased serum alanine aminotransferase values (above 60 IUll) for more than six months. Subgroup lb comprised 14 subjects (eight men) with a chance finding of abnormal serum alanine aminotransferase activity in the absence of evidence of liver disease. Group 2 comprised 43 subjects (25 men) without a clinical history of liver disease or enzyme abnormality. Sixty eight randomly selected anti-HCV negative blood donors (40 men) served as controls (group 3). Other criteria for selection as controls were as in groups 1 and 2.
Blood donors' partners (n= 154; 65 men), who were negative for HIV, had no history of drug abuse or other known risk factors, and engaged only in heterosexual activity, were accepted after accurate history taking
